Evidence map›Paper›PMID 12517470›Full record

ReviewLancet (London, England)2003

The common cold.

Terho Heikkinen, Asko Järvinen

3 registry-linked trialsOpen access · bronzeAbstract readReview
In one paragraph

Review in Lancet (London, England), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 434 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
434citing papers in PubMed, 12 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05819190 nacompletednot on this mapstarted 2022, after this paper: background citation

Efficacy and Safety of Healsea® Hypertonic Nasal Spray 2.7% in the Treatment of Acute Infectious Rhinitis in Adults

TypeinterventionalSponsorLallemand Pharma AGRan2022 to 2023Enrolled200ConditionsCommon ColdArmsHealsea Rescue*, Placebo
NCT05819203 nacompletednot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of Healsea® Babykids in the Treatment of Acute Infectious Rhinitis Symptoms in Children

TypeinterventionalSponsorLallemand Pharma AGRan2023 to 2023Enrolled200ConditionsCommon Cold, Rhinitis ViralArmsHealsea Babykids, Placebo
NCT06531707 phase3unknown statusnot on this mapstarted 2024, after this paper: background citation

Efficacy and Safety of Ibuprofen/Loratadine Fixed-dose Combination Versus the Fixed-dose Administration of Monotherapy as Symptomatic Treatment for Patients With the Common Cold

TypeinterventionalSponsorLaboratorios Silanes S.A. de C.V.Ran2024 to 2025Enrolled177ConditionsCommon ColdArmsIbuprofen + Loratadine fixed dose, Ibuprofen, Loratadine
3 · Its place in the literature

Who cites it

434 citing papers in PubMed, 12 syntheses or guidelines pooled it, 1,046 citations in OpenAlex.

  1. Pooled it
  2. Global meta-analysis of short-term associations between ambient temperature and pathogen-specific respiratory infections, 2004 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
    Pooled it
  3. Frontiers in immunology · 2025
    Pooled it
  4. Pooled it
  5. Vaccines for the common cold.The Cochrane database of systematic reviews · 2022
    Pooled it
  6. Oral antihistamine-decongestant-analgesic combinations for the common cold.The Cochrane database of systematic reviews · 2022
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Efficacy and safety of AtusinBMC pulmonary medicine · 2025
    Trial
  14. Trial
  15. Trial
  16. Rapid microbiological respiratory point-of-care testing: a qualitative study with primary care clinicians.The British journal of general practice : the journal of the Royal College of General Practitioners · 2025
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

374 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Terho HeikkinenDepartment of Paediatrics, Turku University Hospital, Turku, Finland. terho.heikkinen@utu.fi
Asko Järvinen
Helsinki University Hospital · FITurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite great advances in medicine, the common cold continues to be a great burden on society in terms of human suffering and economic losses. Of the several viruses that cause the disease, the role of rhinoviruses is most prominent. About a quarter of all colds are still without proven cause, and the recent discovery of human metapneumovirus suggests that other viruses could remain undiscovered. Research into the inflammatory mechanisms of the common cold has elucidated the complexity of the virus-host relation. Increasing evidence is also available for the central role of viruses in predisposing to complications. New antivirals for the treatment of colds are being developed, but optimum use of these agents would require rapid detection of the specific virus causing the infection. Although vaccines against many respiratory viruses could also become available, the ultimate prevention of the common cold seems to remain a distant aim.

Indexed as

Common ColdRespiratory Tract DiseasesAdultAge DistributionAntiviral AgentsChildFemaleHumansIncidenceInfantMaleSeasonsAntiviral Agents

Identifiers

PMID12517470
PMCPMC7112468
OpenAlexW2153771979

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.